Presentation is loading. Please wait.

Presentation is loading. Please wait.

Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung  Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD,

Published byAshley Fisher Modified over 5 years ago

Similar presentations

Presentation on theme: "Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung  Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD,"— Presentation transcript:

1 Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung 
Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD, Kouya Shiraishi, PhD, Koh Furuta, MD, PhD, Yoko Shimada, MFSc, Hitoshi Katai, MD, PhD, Shun-ichi Watanabe, MD, PhD, Hisao Asamura, MD, PhD, Takashi Kohno, PhD, Koji Tsuta, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 2, Pages (February 2016) DOI: /j.jtho Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 A representative image of ciliated muconodular papillary tumors with hematoxylin–eosin staining. The epithelial components of the lesions consisted of a mixture of ciliated columnar cells (arrow), mucous cells (asterisk), and basal cells (arrowhead). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 The results of the mutation analyses for 10 ciliated muconodular papillary tumors. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Immunohistochemical analyses of the BRAF-V600E ciliated muconodular papillary tumors. Each of the three epithelial components (i.e., ciliated columnar cells, mucous cells, and basal cells) exhibited cytoplasmic staining for BRAF-V600E. The monoclonal antibody also strongly cross-reacted with the cilia of the columnar cells (the internal positive control). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung  Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD,"

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer
Clinicopathological and biological assessment of lung cancers with pleural dissemination  Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.

Clinicopathological and biological assessment of lung cancers with pleural dissemination  Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer  Kyohei Masai, MD, Hiroyuki Sakurai,

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer  Kyohei Masai, MD, Hiroyuki Sakurai,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator  Yukio Watanabe, MD, Masahiko Kusumoto, MD, Akihiko Yoshida,

Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator  Yukio Watanabe, MD, Masahiko Kusumoto, MD, Akihiko Yoshida,

Similar presentations

Ads by Google